Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | CA1 | P00915 | 2/20 | 0.39 |
| ▸ | CA2 | P00918 | 2/20 | 0.39 |
| ▸ | CA9 | Q16790 | 2/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.38 |
| ▸ | RAB9A | P51151 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | MIF | P14174 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5567091 | 1.00 | POLB (0.43) | POLBATMLMNASMN1; SMN2CA12 | |
| SCHEMBL670164 | 1.00 | POLB (0.43) | POLBATMLMNASMN1; SMN2CA12 | |
| SCHEMBL22798569 | 0.92 | POLB (0.44) | POLBATMLMNASMN1; SMN2CA12 | |
| SCHEMBL8196306 | 0.92 | POLB (0.44) | POLBATMLMNASMN1; SMN2CA12 | |
| SCHEMBL6764378 | 0.89 | SYK (0.41) | POLBATMSMN1; SMN2NPC1RAB9A | |
| SCHEMBL6764370 | 0.89 | SYK (0.41) | POLBCA12CA1 | |
| SCHEMBL6764374 | 0.89 | SYK (0.41) | POLBCA12CA1 | |
| SCHEMBL14271350 | 0.87 | ALDH1A1 (0.40) | POLBATM | |
| SCHEMBL6624590 | 0.86 | L3MBTL1 (0.39) | SMN1; SMN2NPC1RAB9AHTT | |
| SCHEMBL9254620 | 0.80 | POLB (0.47) | POLBLMNASMN1; SMN2CA12CA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 155 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230257727-A1 | MODIFIED CLEAVASES, USES THEREOF AND RELATED KITS | Encodia, Inc. (US) | 2023-08-17 | — | — | US | claimed |
| US-11427814-B2 | Modified cleavases, uses thereof and related kits | Encodia, Inc. (US) | 2022-08-30 | — | — | US | claimed |
| US-20210214701-A1 | MODIFIED CLEAVASES, USES THEREOF AND RELATED KITS | Encodia, Inc. (US) | 2021-07-15 | — | — | US | claimed |
| EP-4127157-B1 | MODIFIED DIPEPTIDE CLEAVASES, USES THEREOF AND RELATED KITS | ENCODIA INC (US) | 2026-02-11 | — | — | EP | disclosed |
| US-12472267-B2 | Compositions containing nucleic acid nanoparticles with modular functionality | Sixfold Bioscience Ltd. (GB) | 2025-11-18 | — | — | US | disclosed |
| EP-4646595-A1 | PEPTIDE SEQUENCER | Oregon Health & Science University (US) | 2025-11-12 | — | — | EP | disclosed |
| US-20250102513-A1 | KITS FOR ANALYSIS USING NUCLEIC ACID ENCODING AND/OR LABEL | Encodia, Inc. (US) | 2025-03-27 | — | — | US | disclosed |
| US-12122736-B2 | Salty taste-enhancing agent and manufacturing method therefor, and salty taste-enhancing method | NISSAN FOODS HOLDINGS CO., LTD. (JP) | 2024-10-22 | — | — | US | disclosed |
| EP-3343225-B1 | METHOD OF PREPARING SAMPLE FOR ANALYSIS AND ANALYSIS METHOD | SHIMADZU CORP (JP) | 2024-08-07 | — | — | EP | disclosed |
| WO-2024148174-A1 | PEPTIDE SEQUENCER | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2024-07-11 | — | — | WO | disclosed |
| US-20240158829-A1 | METHODS FOR BIOMOLECULE ANALYSIS EMPLOYING MULTI-COMPONENT DETECTION AGENT AND RELATED KITS | DF PEPTIDE ACQUISITION LLC | 2024-05-16 | — | — | US | disclosed |
| US-6284914-B1 | HYDROXAMIC ACID DERIVATIVES | FUJI YAKUHIN KOGYO KABUSHIKI KAISHA (JP) | 2001-09-04 | — | — | US | disclosed |
| US-6235778-B1 | ANTICOAGULANTS | 3-DIMENSIONAL PHARMACEUTICALS, INC. | 2001-05-22 | — | — | US | disclosed |
| EP-1089973-A1 | AMIDINO AND GUANIDINO AZETIDINONE TRYPTASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2001-04-11 | — | — | EP | disclosed |
| EP-1081132-A1 | HYDROXAMIC ACID DERIVATIVES AND MEDICINAL UTILIZATION THEREOF | Welfide Corporation (JP) | 2001-03-07 | — | — | EP | disclosed |
| US-6147114-A | HYDROXAMIC ACID DERIVATIVES FROM TUMOR NECROSIS FACTOR CONVERTING ENZYME | FUJI YAKUHIN KOGYO KABUSHIKI KAISHA (JP) | 2000-11-14 | — | — | US | disclosed |
| WO-1999067215-A1 | AMIDINO AND GUANIDINO AZETIDINONE TRYPTASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 1999-12-29 | — | — | WO | disclosed |
| US-5935932-A | Bradykinin antagonists containing pentafluorophenylalanine | UNIVERSITY TECHNOLOGY CORPORATION (US) | 1999-08-10 | — | — | US | disclosed |
| EP-0850950-A1 | PEPTIDE DERIVATIVES | DAIICHI PHARMACEUTICAL CO., LTD. (JP) | 1998-07-01 | — | — | EP | disclosed |
| EP-0832875-A1 | HIGHLY WATER-SOLUBLE METALLOPROTEINASE INHIBITOR | FUJI YAKUHIN KOGYO KABUSHIKI KAISHA (JP) | 1998-04-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12122736-B2 | Salty taste-enhancing agent and manufacturing method therefor, and salty taste-enhancing method | TAS2R8, TAS2R13, TAS2R38 | POLB 4632/4885ATM 3310/4885LMNA 4535/4885 |
| US-12472267-B2 | Compositions containing nucleic acid nanoparticles with modular functionality | NCL, NSUN3, POLN | POLB 73/4885ATM 3932/4885LMNA 514/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.